­
­
­
­

Inventi Impact: Clinical Research

Articles

  • Inventi:pcr/27031/18
    Chromium-Containing Traditional Chinese Medicine, Tianmai Xiaoke Tablet, for Newly Diagnosed\nType 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review of Randomized Clinical Trials
    01-Jan-1970 Review 2018 : October - December
    Yuming Gu, Xuemin Xu, Zhe Wang, Yunsheng Xu, Xiuzhi Liu, Lejun Cao, Xueyang Wang, Zhengxin Li, Bo Feng

    Objective. Chromium-containing traditional Chinese medicine Tianmai Xiaoke tablet (TMXKT) is approved for treating newly\ndiagnosed type 2 diabetes mellitus (T2DM) in China.This review aimed to compile the evidence from randomized clinical trials\n(RCTs) and quantify the effects of TMXKT on newly diagnosed T2DM. Methods. Seven online databases were investigated up\nto March 20, 2017. The meta-analysis included RCTs investigating the treatment of newly diagnosed T2DM, in which TMXKT\ncombined with conventional therapy was compared with placebo or conventional therapy. The risk of bias was evaluated using\nthe Cochrane Collaboration tool. The estimated mean difference (MD) and the standardized mean difference were within 95%\nconfidence intervals (CI) with respect to the interstudy heterogeneity. The outcomes were measured using fasting blood glucose\n(FBG), 2-h postprandial blood glucose (2hPG), glycosylated hemoglobin A1c (HbA1c), and body mass index (BMI) levels. Results.\nTMXKT combined with conventional therapy lowered FBG level (MD = âË?â??0.68, 95% CI âË?â??0.90 to âË?â??0.45,

    How to Cite this Article
    Yuming Gu, Xuemin Xu, Zhe Wang, et al.,\nâ??Chromium-Containing Traditional Chinese Medicine, Tianmai\nXiaoke Tablet, for Newly Diagnosed Type 2 Diabetes Mellitus: A\nMeta-Analysis and Systematic Review of Randomized Clinical\nTrials,â? Evidence-Based Complementary and Alternative Medicine,\nvol. 2018, Article ID 3708637, 8 pages, 2018. https://\ndoi.org/10.1155/2018/3708637, https://creativecommons.org/\nlicenses/by/4.0/.
    Download Full Text